Taselisib

Drug Profile

Taselisib

Alternative Names: GDC 0032; RG-7604

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; Netherlands Cancer Institute
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Benzazepines; Oxazepines; Pyrazoles; Small molecules; Triazoles
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II/III Non-small cell lung cancer
  • Phase I/II Gynaecological cancer
  • Phase I Solid tumours

Most Recent Events

  • 02 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Breast cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 13 Mar 2017 Genentech completes the phase II LORELEI trial in Breast cancer (Neoadjuvant therapy, Combination therapy, Early-stage disease, First line therapy) in USA, Australia, Austria, Belgium, Brazil, Chile, Czech Republic, El Salvador, France, Germany, Guatemala, Hungary, Italy, South Korea, Mexico, Panama, Peru, Poland, Portugal, Spain, Switzerland, United Kingdom (NCT02273973; EudraCT2013-000568-28)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top